Research programme: antibody-drug conjugates - Seattle Genetics

Drug Profile

Research programme: antibody-drug conjugates - Seattle Genetics

Alternative Names: SGN CD48A

Latest Information Update: 02 Nov 2016

Price : $50

At a glance

  • Originator Seattle Genetics
  • Class Benzodiazepines; Drug conjugates; Immunotoxins; Monoclonal antibodies; Pyrroles
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 27 Oct 2016 Seattle Genetics plans a phase I trial for Multiple myeloma
  • 23 Oct 2013 Preclinical development is ongoing in the US
  • 22 Jun 2011 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top